Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
주식 순위 #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
주가
$0.1559364
마지막 동기화: 2026-09-18
시가총액
$195.17K
변동 (1일)
6.60%
변동 (1년)
-30.91%
국가
GB
거래 Fusion Antibodies plc (FAB)

카테고리

Fusion Antibodies plc (FAB)의 P/S 비율
September 2026 기준 P/S 비율 TTM: 7.25
Fusion Antibodies plc의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 7.25입니다. 2024년 말 기준 P/S 비율은 1.88였습니다.
Fusion Antibodies plc의 P/S 비율 기록 (2013 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
2026 (TTM) 7.25 141.79%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
10.44 43.99%
US
12.01 65.53%
NL
26.12 260.14%
US
3.76 -48.23%
AU
- -
CH